Infinity Pharmaceuticals, Inc. INFI
We take great care to ensure that the data presented and summarized in this overview for INFINITY PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in INFI
Top Purchases
Top Sells
About INFI
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at INFI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2023
|
Adelene Q Perkins Director |
SELL
Open market or private sale
|
Direct |
410,196
-25.87%
|
$0
$0.07 P/Share
|
|
Sep 09
2023
|
Adelene Q Perkins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
768,133
+32.64%
|
-
|
|
Aug 02
2022
|
Stephane Peluso Chief Scientific Officer |
BUY
Open market or private sale
|
Direct |
14,994
+28.81%
|
$0
$0.66 P/Share
|
|
Aug 02
2022
|
Stephane Peluso Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.0%
|
-
|
|
Jun 16
2022
|
Brian Schwartz |
BUY
Grant, award, or other acquisition
|
Direct |
30,919
+50.0%
|
$0
$0.68 P/Share
|
|
Jun 16
2022
|
Anthony B Evnin |
BUY
Grant, award, or other acquisition
|
Direct |
46,378
+17.72%
|
$0
$0.68 P/Share
|
|
Jun 10
2021
|
Anthony B Evnin |
BUY
Grant, award, or other acquisition
|
Direct |
3,061
+1.78%
|
$9,183
$3.43 P/Share
|
|
Jun 10
2021
|
David W Beier |
BUY
Grant, award, or other acquisition
|
Direct |
3,061
+25.86%
|
$9,183
$3.43 P/Share
|
|
May 14
2021
|
Norman C Selby |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+25.0%
|
$0
$0.92 P/Share
|
|
Feb 11
2021
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,260,085
-21.67%
|
$11,300,425
$5.37 P/Share
|
|
Jan 22
2021
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,848,520
-38.53%
|
$23,394,080
$4.14 P/Share
|
|
Dec 13
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
175,000
+1.21%
|
$175,000
$1.2 P/Share
|
|
Nov 28
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.51%
|
$100,000
$1.3 P/Share
|
|
Nov 21
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,700
+0.05%
|
$4,700
$1.35 P/Share
|
|
Nov 19
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,465,126
+3.97%
|
$1,465,126
$1.36 P/Share
|
|
Nov 15
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
91,474
+0.67%
|
$91,474
$1.35 P/Share
|
|
Nov 14
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
210,250
+1.55%
|
$210,250
$1.34 P/Share
|
|
Nov 13
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
604,208
+4.78%
|
$604,208
$1.35 P/Share
|
|
Jun 21
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
425,531
+3.02%
|
$425,531
$1.65 P/Share
|
|
Jun 19
2018
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
3,516,560
+19.0%
|
$3,516,560
$1.65 P/Share
|